[ Price : $8.95]
Hyman, Phelps and McNamara attorneys say FDA must fix its broken system of announcing complex decisions on questions arising at th...[ Price : $8.95]
Two Yale law school professors say FDA should staunchly defend its current regulatory regime restricting company promotion of off-...[ Price : $8.95]
Five stakeholders raise concerns about an FDA draft guidance on when a new 510(k) should be submitted for a change to an existing ...[ Price : $8.95]
In its latest batch of Warning Letters, FDA cites Innovative Compounding Pharmacy and Valeant Pharmaceuticals.[ Price : $8.95]
Federal Register Final Rule: FDA issues a final rule to amend the regulations to reflect organization change in the agency and to ...[ Price : $8.95]
Federal Register Notice: FDA establishes a public docket to collect comments related to a proposed Study Data Standardization Plan...[ Price : $8.95]
FDA places a clinical hold on a BioInvent International Phase 2 study of the antibody BI-505 in patients with multiple myeloma.[ Price : $8.95]
FDAs New York District Office warns Valeant Pharmaceuticals about Quality System regulation problems in its development of specifi...